Durvalumab + Tremelimumab

Phase 1/2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Trial Timeline

Oct 4, 2018 → Jun 30, 2023

NCT ID

NCT03618134

About Durvalumab + Tremelimumab

Durvalumab + Tremelimumab is a phase 1/2 stage product being developed by AstraZeneca for Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8. The current trial status is terminated. This product is registered under clinical trial identifier NCT03618134. Target conditions include Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05345678	Pre-clinical	Completed	—	—	Unresectable Hepatocellular Carcinoma
NCT07081633	Phase 2	Recruiting	Aug 5, 2025	Dec 31, 2028	Hepatocellular Carcinoma
NCT05883644	Phase 3	Active	Jun 27, 2023	Sep 30, 2026	Advanced Hepatocellular Carcinoma
NCT05701488	Phase 1	Recruiting	Apr 21, 2023	Oct 1, 2026	Resectable Hepatocellular Carcinoma
NCT05557838	Phase 3	Recruiting	Feb 22, 2023	Mar 31, 2025	Hepatocellular Carcinoma
NCT04430452	Phase 2	Recruiting	Feb 4, 2022	Jul 31, 2029	Advanced Hepatocellular Carcinoma
NCT05000710	Phase 2	Active	Dec 9, 2021	Dec 1, 2026	Metastatic or Locally Advanced NSCLC
NCT04499053	Phase 2	Recruiting	Dec 9, 2020	Dec 1, 2027	Carcinoma, Non-Small Cell Lung
NCT04395079	Phase 2	Active	Aug 7, 2020	Dec 1, 2026	Metastatic Malignant Female Reproductive System Neoplasm
NCT04238637	Phase 2	Active	Nov 1, 2019	Dec 1, 2027	Intrahepatic Cholangiocarcinoma
NCT03638141	Phase 2	Completed	Oct 2, 2019	Aug 20, 2024	Intermediate Stage of Hepatocellular Carcinoma
NCT03702179	Phase 2	Completed	Nov 19, 2018	Aug 16, 2022	Invasive Bladder Cancer
NCT03704480	Phase 2	Active	Nov 9, 2018	Dec 31, 2025	Advanced Biliary Tract Carcinoma
NCT03601455	Phase 2	Active	Oct 26, 2018	Jan 31, 2027	Bladder Urothelial Carcinoma
NCT03618134	Phase 1/2	Terminated	Oct 4, 2018	Jun 30, 2023	Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8
NCT03703297	Phase 3	Active	Sep 27, 2018	Oct 23, 2026	Small Cell Lung Cancer
NCT03624231	Phase 2	Completed	Aug 15, 2018	Aug 17, 2023	Squamous Cell Carcinoma of the Head and Neck
NCT03288532	Phase 3	Recruiting	Jul 19, 2018	Dec 1, 2034	Renal Cell Carcinoma
NCT03283605	Phase 1/2	Active	Jul 17, 2018	Dec 31, 2024	Head and Neck Squamous Cell Carcinoma
NCT03277482	Phase 1	Terminated	Jun 1, 2018	Jul 15, 2022	Recurrent Gynecological Cancer

Competing Products

20 competing products in Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8

See all competitors

Product	Company	Stage	Hype Score
Lecanemab + Placebo	Eisai	Phase 3	77
Cetuximab + Cisplatin	Eli Lilly	Phase 2	52
Posaconazole	Merck	Approved	85
Rebif®	Merck	Phase 3	77
Blinatumomab + olverembatinib	Amgen	Phase 2	51
Binimetinib + Nivolumab	Bristol Myers Squibb	Phase 2	51
Fluconazole (BAYT006267) 150 mg capsules + Fluconazole 150 mg capsules (DiflucanTM)	Bayer	Phase 1	30
Finerenone (BAY 94-8862) PEG solution + Finerenone (BAY 94-8862) immediate release tablet + Eplerenone (Inspra®) + Placebo	Bayer	Phase 1	30
Rivaroxaban (BAY 59-7939, Xarelto) in ODT form + Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form	Bayer	Phase 1	30
Naproxen sodium and diphenhydramine hydrochloride soft capsules + Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)	Bayer	Phase 1	30
Fulacimstat (BAY1142524)	Bayer	Phase 1	30
Vilaprisan (BAY 1002670) + Vilaprisan Placebo + Microgynon + Microgynon Placebo	Bayer	Phase 1	30
Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil	Bayer	Phase 1	30
BAY1817080 + Placebo + Itraconazole	Bayer	Phase 1	30
BAY1902607 + Placebo	Bayer	Phase 1	30
Fosrenol ODT (Lanthanum Carbonate, BAY77-1931) + Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)	Bayer	Phase 1	30
Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg + Placebo	Bayer	Phase 1	30
Neladenoson bialanate (BAY 1067197)	Bayer	Phase 1	30
Riociguat (Adempas, BAY 63-2521)	Bayer	Phase 1	30
Vilaprisan (BAY1002670)	Bayer	Phase 1	30

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved